Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: Primary care

Similar Outcomes with Early or Late Mobilization After Rotator Cuff Repair

Rita Buckley  |  February 6, 2017

NEW YORK (Reuters Health)—Early or late mobilization after rotator cuff surgery appears to yield similar outcomes, according to a new meta-analysis. Dr. Bruno Fles Mazuquin from the University of Central Lancashire in the U.K., and colleagues conducted an overview of systematic reviews comparing the effectiveness of early and conservative rehabilitation after rotator cuff repair. The…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:joint mobilizationPhysical Therapyrotator cuffshouldersurgery

Biosimilar Update: ACR Says FDA Draft Guidance Is Promising & Biosimilar to Humira (Adalimumab) Enters Regulatory Review

Michele B. Kaufman, PharmD, BCGP  |  February 1, 2017

The ACR has released a statement, responding positively to the release of the latest U.S. Food and Drug Administration (FDA) draft guidance on biosimilar drug development. Also, BI 695501, a biosimilar to Humira (adalimumab) made by Boehringer Ingelheim, has been accepted for regulatory review in both the U.S. and Europe. ACR Responds to FDA Biosimilar…

Filed under:Biologics/DMARDsDrug Updates Tagged with:adalimumabBI 695501BiosimilarsFDAFood and Drug AdministrationHumira

Updated EULAR Recommendations for Early Arthritis; Plus FDA Approves New Abuse-Deterrent Morphine Sulfate

Michele B. Kaufman, PharmD, BCGP  |  January 25, 2017

EULAR has updated its recommendations for the management of early arthritis, outlining aspects of diagnosis and drug treatments…

Filed under:AnalgesicsConditionsDrug UpdatesEULAR/OtherMeeting ReportsRheumatoid Arthritis Tagged with:Arthritisearly arthritisEULARFDAFood and Drug AdministrationOpioidsrecommendationsTreatment

Guselkumab Improves Active Psoriatic Arthritis

Michele B. Kaufman, PharmD, BCGP, & Lara C. Pullen, PhD  |  January 11, 2017

A study showed that guselkumab may decrease symptoms of psoriatic arthritis and improve quality of life in adult patients…

Filed under:Biologics/DMARDsDrug Updates

FDA Update: FX006 Promising for Knee OA; Pioglitazone Linked to Bladder Cancer Risk; & HIV Drug Gets New Labeling

Michele B. Kaufman, PharmD, BCGP  |  January 4, 2017

The makers of FX006, a steroid injection for treating pain in patients with knee osteoarthritis, have submitted a new drug application to the FDA…

Filed under:AnalgesicsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:CancerFDAFood and Drug AdministrationFX006HIVkneeKnee Osteoarthritis (OA)Painpioglitazone

Does Telephone Coaching Enhance Physical Activity Programs?

Arthritis Care & Research  |  January 3, 2017

Health coaching by telephone is increasingly being used to assist in chronic disease self-management. A recent study examined the benefits of simultaneous health coaching via telephone as an addition to a physiotherapist-prescribed home-based physical activity program for patients with knee OA. Although participants receiving additional coaching had a short-term improvement in adherence, changes in pain and function did not differ between the study’s groups at six months…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:Exerciseexercise therapykneeKnee Osteoarthritis (OA)Physical Therapy

Lesinurad with Allopurinol When Allopurinol Alone Is Insufficient

Arthritis & Rheumatology  |  December 29, 2016

Current guidelines for the long-term management of gout recommend a combination of lifestyle management and/or pharmacotherapy to lower serum UA levels to <6.0 mg/dL in most patients or <5.0 mg/dL in patients with more severe disease. Allopurinol is the most widely used xanthine oxidase inhibitor and is recommended in treatment guidelines as a first-line urate-lowering…

Filed under:ConditionsGout and Crystalline ArthritisResearch Rheum Tagged with:AllopurinolArthritis & RheumatologyGoutlesinuradResearchUric acid

Rheumatology Drug Updates: Celecoxib and Cardiovascular Safety Trial Results Reviewed

Michele B. Kaufman, PharmD, BCGP  |  December 13, 2016

Nonsteroidal anti-inflammatory drugs (NSAIDs) have been used therapeutically since the 1960s.1 Evidence of adverse cardiovascular outcomes led to the withdrawal of the selective COX-2 inhibitor rofecoxib in September 2004, when the question of cardiovascular safety of NSAIDs first came into the limelight.2 Valdecoxib (Bextra) was subsequently withdrawn from the market in April 2005 due to…

Filed under:AnalgesicsDrug UpdatesResearch Rheum Tagged with:anti-inflammatorycardiovascularcelecoxib (Elyxyb)drugFDAmortalityNSAIDoutcomePrecision trialResearchrheumatologyriskSafety

Celecoxib & Cardiovascular Death: NSAID Safety Under Review

Michele B. Kaufman, PharmD, BCGP  |  December 7, 2016

A recent study showed that at moderate doses celecoxib may be noninferior with respect to cardiovascular safety compared with ibuprofen or naproxen…

Filed under:AnalgesicsDrug Updates Tagged with:cardiovascularFDAFood and Drug AdministrationheartNSAIDsPREC

Rheumatology Fellowship Work in Ethiopia Reveals Gaps in Practical Management of Rheumatic Diseases

Mary Abraham, MD, MBA, with Frehyiwot Ayele, MD  |  November 16, 2016

The first month of my last year of rheumatology fellowship began in Addis Ababa, Ethiopia, at Black Lion Hospital, a tertiary university medical center, where I [Dr. Mary Abraham] started an Emory-sponsored global health rotation. Although a very different beginning to my fellowship year, my experiences at Black Lion reminded me of my passion to…

Filed under:Rheumatoid Arthritis Tagged with:Black Lion HospitalDr. Frehyiwot AyeleDr. Mary AbrahamEthiopiafellowshipInternationalpatient careresidentrheumatology

  • « Previous Page
  • 1
  • …
  • 107
  • 108
  • 109
  • 110
  • 111
  • …
  • 137
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences